title: Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities.
abstract: Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL). The nature of the pruritus experienced by CTCL patients is complex, involving different pathways and cell mediators, thus making it poorly responsive to conventional anti-itch therapies. Recent reports highlight the role of interleukin 31 (IL-31) as a novel cytokine involved in the pathogenesis of pruritus in atopic dermatitis and CTCL. Here we provide both in vivo and in vitro evidence suggesting that histone deacetylase (HDAC) inhibitors may mitigate itch through lowering of levels of IL-31-expressing T cells. Furthermore, we demonstrate that chemokine receptor type-4 (CCR4)-bearing T cells are a main source of IL-31 in CTCL, and that neutralizing the IL-31 pathway through targeting of the CCR4-expressing T cells may represent a promising therapeutic strategy for symptomatic relief in CTCL.
authors.affiliation: Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: filiberto.cedenolaurent@uphs.upenn.edu.
authors.forename: Filiberto
authors.initials: F
authors.lastname: Cedeno-Laurent
authors.affiliation: Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Elisha M
authors.initials: EM
authors.lastname: Singer
authors.affiliation: Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Maria
authors.initials: M
authors.lastname: Wysocka
authors.affiliation: Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Bernice M
authors.initials: BM
authors.lastname: Benoit
authors.affiliation: Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Carmela C
authors.initials: CC
authors.lastname: Vittorio
authors.affiliation: Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Ellen J
authors.initials: EJ
authors.lastname: Kim
authors.affiliation: Department of Dermatology, Temple University School of Medicine, Philadelphia, PA, USA.
authors.forename: Gil
authors.initials: G
authors.lastname: Yosipovitch
authors.affiliation: Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Alain H
authors.initials: AH
authors.lastname: Rook
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D047630:Depsipeptides / Q000494:pharmacology / Q000627:therapeutic use; D003907:Dexamethasone / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology / Q000627:therapeutic use; D066298:In Vitro Techniques; D007378:Interleukins / Q000276:immunology*; D016410:Lymphoma, T-Cell, Cutaneous / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011537:Pruritus / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D012333:RNA, Messenger / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D016896:Treatment Outcome; D000077337:Vorinostat
chemical_list: D047630:Depsipeptides; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; C502187:IL31 protein, human; D007378:Interleukins; D012333:RNA, Messenger; D000077337:Vorinostat; D003907:Dexamethasone; C087123:romidepsin
keywords: CTCL; IL-31; Immunotherapy; Pruritus